Thomas Hutson, DO, PharmD, discusses key safety considerations with cabozantinib in patients with metastatic renal cell carcinoma.
Thomas Hutson, DO, PharmD, director, Urologic Oncology Program, co-chair, Urologic Cancer Research and Treatment Center, Baylor University Medical Center, professor of medicine, Texas A&M College of Medicine, discusses key safety considerations with cabozantinib (Cabometyx) in patients with metastatic renal cell carcinoma (mRCC).
Cabozantinib is a potential treatment option for patients with mRCC, says Hutson. Initially, patients receiving cabozantinib should be monitored every 2 to 3 weeks for blood pressure changes, mouth sores, diarrhea, and hypertension, Hutson explains. Once dosing and adverse effect (AE) management strategies are in place, patients can be monitored every 6 to 8 weeks, Hutson says.
Additionally, it is important to establish a relationship with the patient in which they feel comfortable relaying any AEs that arise and understand that dose reduction is an option, concludes Hutson.